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Abstract: The activity of cysteine peptidases (cathepsins B and L) was estimated in homogenates of tissues sampled
during surgery from 60 patients operated due to colorectal tumors. The results were compared to those obtained
using tissues in which histopathology disclosed no tumorous cells, obtained from 20 patients of the same group,
treated as a control. Activity of the enzymes was inhibited using cysteine peptidase inhibitors isolated from chicken
egg proteins. Application of the inhibitors was found to inhibit activity of the enzymes which play a key role in
tumor development. It is suggested that in future the inhibitors may provide a component of new generation drugs
in the so-called inhibitor therapy. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 670–676)
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Introduction
The incidence of malignant colorectal tumors is very
high: it is estimated that 6% of the human popula-
tion will develop colorectal cancer during their life,
and 40% of those will die because of the tumor [1].
An increased prevalence of tumors has been noted in
industrialized regions, which is linked to elevated lev-
els of toxic substances emitted to the atmosphere [2].
Epidemiological and statistical results of studies
conducted in Poland to date have confirmed that
around 60% of tumors were induced by agents rep-
resenting environmental pollution with carcinogens
[3]. Reports suggest that probably in tumors of the
alimentary tract at first a suppressor gene appears,
the altered APC gene, located on chromosome 5
(MCC-mutated in colorectal cancer) and DCC (de-
leted in colorectal carcinoma) genes, coding for pro-
teins responsible for cellular adhesion, which subse-
quently control interaction of the neoplastic cell with
normal cells. Finally, the changes may lead to devel-
opment of a tumor. The multi-step process of chang-
es in a tumor of alimentary tract (polyp Æ carcino-
ma) involves few gradual mutations in a genome of
normal cells [4, 5].
The results of studies conducted by several inde-
pendent teams suggest that the changes involve the
so-called cascade of enzymatic alterations. The pro-
cess reflects the fact that enzymes involved in the pro-
cess participate in reciprocal autoactivation. At the
beginning, they appear in the human body in the form
of inactive precursors, which do not manifest their
biological function until they are enzymatically acti-
vated [6, 7]. Justifiable assumptions have been put
forward that the cause of appearance and develop-
ment of neoplastic processes involves overexpression
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of proteolytic enzymes, compared to an activity of
cathepsins produced in the body their autogenic in-
hibitors, capable of inhibiting activity of the proteas-
es. The correlation between active metalloproteinas-
es, elastases, plasminogen activator and their auto-
genic inhibitors has been dissected in detail [8]. In-
hibitors of cysteine peptidases have been also
examined, which by inhibition of cathepsin B and L
may additionally restrict formation of collagenase,
elastase, collagen activator and other metalloprotein-
ase active forms or key enzymes involved in the de-
composition of normal tissues. It is assumed that the
process may be controlled using inhibitors isolated
from various extracorporeal sources. The appearance
in a body of active cathepsin D results in activation of
cysteine peptidases (mainly cathepsins B and L). Re-
sults of studies have confirmed that appearance of
the enzyme’s active forms results in activation of sev-
eral proteolytic enzymes from their inactive precur-
sors, including, first of all, metalloproteinases, plas-
minogen activator, elastases and several other en-
zymes. In parallel with cysteine peptidases, the en-
zymes induce degradation of their own tissues. They
are also decisive for processes associated with neo-
plastic alterations, such as transformation of normal
to neoplastic cells, invasion and development of me-
tastases or angiogenesis.
However, no inhibitors have been obtained until
now which would inhibit the activity of the enzymes
in vivo but which exert no toxicity [9–12]. Activity of
proteolytic enzymes associated with neoplasia is con-
trolled by their specific inhibitors, manifested in the
body as autogenic inhibitors. Japanese investigators
have demonstrated a significant involvement of au-
togenic cystatin SN in the development of lesions in
a colorectal tumor. A significant correlation was dis-
closed of the enzyme level and markers such as CEA
and CA19-9, estimated by the ELISA technique [13].
In this case, research results from another Japanese
team proved extremely interesting. They demonstrat-
ed a very high similarity between the structure of cys-
tatin SN, C and its analog isolated from egg proteins.
It may be assumed that cystatin obtained from egg
proteins may interchangeably be applied with inhibi-
tors of cysteine peptidases, which control overexpres-
sion of cathepsins, cysteine peptidases in pathogenic
conditions, including cathepsins B, L or K in colorec-
tal cancer [14].
Material and methods
Tissue samples of around 1 g were sampled intraoperative-
ly from 60 patients with a diagnosis of colorectal adenocar-
cinoma and were stored in a freezer at a temperature of
–20°C for around three months. Apart from the known and
applied routine diagnostic techniques performed before the
procedure, histopathology was also applied. The control
group included tissue samples free of cancerous lesions. The
age of the operated patients of either sex ranged between
35 and 73 years. Tumor advancement was evaluated in rou-
tine histopathological examination, using hematoxylin- and
eosin-stained preparations (H&E evaluation). Estimation
of cancerous cell presence followed rules provided by UICC,
based on the TNM scheme (T — tumor size, N — node
invasions, M — metastasis). In the modified scale of Dukes,
the tissues originated from ten patients (17%) representing
tumor advancement stage A, from 20 patients (33%) with
stage B, 12 patients (20%) with stage C, and 18 patients
(30%) with stage D [15].
After collecting 20 to 30 samples, they were thawed,
washed with saline and divided into two parts. One was
embedded in paraffin and subjected to immunohistopatho-
logical examination, and the other was homogenized in
a triple amount (weightwise) of 10 mM Tris-HCl buffer, pH
7.4, supplemented with 0.25 M sucrose, 1 mM DTT (dithio-
threitol), 0.1 mM ATP (adenosine-triphosphate) and
0.1 mM CaCl2. The homogenates were centrifuged at 100,000 g
for one hour at 4°C. After centrifugation the supernatant
was collected and stored at –70°C. After 60 samples of can-
cerous tissues were processed in this way, activity of their
cysteine proteases was estimated using spectrofluorometry.
Estimation of cathepsin B and L activities. Activities of
cathepsins B and L were estimated using spectrofluoromet-
ric technique of Barrett [16]. Z-Arg-AMC, i.e. benzyloxy-
carbonyl-arginyl-AMC (AMC, alpha methylcoumarin)
served as a substrate. Following hydrolysis, fluorescence of
the released 7-AMC was measured using a spectrofluorim-
eter (Perking Elmer LS 50 B, using illumination at 440 nm
and measuring emission at 370 nm). The fluorescence was
read out using a calibration curve prepared using 7-AMC.
A unit of enzymatic activity (U) involved the amount of
enzyme, calculated per protein, which catalyzed release of
1 nM of 7-AMC per minute.
Inhibitory activity in studied samples was estimated us-
ing the technique of Heidtman [17]. A single unit of inhib-
itory activity was defined as such an amount of an inhibitor
which inhibited respectively cathepsin B and L activities cal-
culated per 1 mg of protein [18]. The calculations took ad-
vantage of Statgraf software. Distribution of the results was
tested using the test of Kolmogorov–Smirnov. All the ex-
amined characters manifested the normal distribution, which
in statistical analysis permitted to apply parametric tests.
Comparison of values between two studied parameters
employed Student’s t test, non-parametric tests of Wilcox
or Kruskall–Wallis. Correlation coefficients were calculat-
ed using Student’s t test for correlation coefficient. All hy-
potheses were tested at the significance level of p < 0.05.
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Results
In the study, cysteine peptidase (cathepsins B and L)
activity was estimated in homogenates of tissues sam-
pled during surgery from 60 patients operated due to
tumors of the large intestine. The results were com-
pared with biological material obtained from 20 pa-
tients of the same group, in which histopathology
failed to disclose the presence of cancerous cells. The
latter samples provided a control group. Activity of
the enzymes was inhibited using cystatin isolated from
hen eggs, which manifested activity of 344.8 units per
mg protein. The amount of the inhibitor was adjust-
ed so that activity of the enzymes was not completely
inhibited but only to 50% to 80% of its original activ-
ity (Table 1).
The subsequent stage of the studies involved ap-
plication of cystatin isolated from hen egg proteins
for inhibition of cathepsin B and L activities in the
obtained homogenates of colorectal tumors. The es-
timations were performed in all the neoplastic sam-
ples and 20 control samples. The first stage involved
determination of such an amount of the inhibitor
which would inhibit cysteine peptidase activity in three
randomly selected samples of homogenates. The re-
sults are presented in Table 2.
The obtained results suggested that optimum re-
sults can be obtained inhibiting activity of cysteine
peptidases in the studied tissue homogenates to the
range of 50% to 60% of their original enzymatic ac-
tivity. In samples of 60 homogenates obtained tissues
of colorectal cancer the enzymatic activity was inhib-
ited using 50 μg cystatin per examined sample. The
results are presented in Tables 3 and 4.
Discussion
This study demonstrates the potential for inhibiting
cysteine peptidase activity in homogenates of tumor-
ous tissues obtained from patients operated due to
colorectal carcinoma using their specific inhibitors
obtained from hen egg proteins. In normal cells, cys-
teine peptidases are contained in lysosomes, in which
they catalyze protein degradation but do not fulfil as
important functions as their analogs in cancer cells:
in the latter they are secreted out of the cell or be-
come attached to their membranes playing a direct
role in processes of tumor aggression. Until now, the
Table 1. Activity of cathepsins B and L in tissue homogenates obtained from 60 patients operated due to a colorectal
tumor, compared to the control group of healthy tissues (344.8 units/mg protein)
Cysteine peptidases in Mean ± SD Range SD
Tumor (n = 60) 286.50 403.20–135.10 60.16
Control (n = 20) 18.7 ± 8.1 12.3–26.9 15.4
Difference between the two groups significant at p £ 0.0001
Table 2. Titration of cathepsin B and L activities using cystatin obtained from egg proteins in three selected samples of
tissue homogenate obtained from colorectal cancer
Activity of cystatin: 344.8 units/mg protein
Activity of cystein + 25 μg ICP/ + 50 μg ICP/ + 100 μg ICP/
peptidases/1.0 mg protein /1.0 mg protein /1.0 mg protein /1.0 mg protein
262.8 (100%) 192.1 (73.8%) 90.1 (65.7%) 13.6 (5.2%)
345.5 (100%) 271.7 (78.6%) 156.2 (54.8%) 58.9 (17.1%)
264.1 (100%) 207.8 (78.7%) 86.1 (67.4%) 23.8 (9.0%)
Table 3. Activity of cysteine peptidases in tissue homogenates of patients operated due to tumor of large intestine
compared to control group (healthy tissues) (344.8 U/ mg protein)
Cathepsin in Mean ± SD Range SD
Tumor 286.50 403.20–135.10 60.15
Control 142.86 252.60–4.80 40.63
% inhibition 49.86 67.00–33.00 7.81
The difference is significant at p £ 0.0001
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Table 4. Inhibition of cysteine peptidase activities in tissue homogenates from patients with colorectal carcinoma.
Estimations were conducted using spectrofluorometry, supplementing every sample of homogenate supernatant with 50 μg
inhibitor (activity of 344.8 U/mg protein)
Sample no. Activity of cathepsin B Cathepsin B and L+ 50 μg % inhibition of cathepsin B
and L/1.0 mg protein  cystatin from egg protein  and L activity
1 262.8 90.1 65.7
2 345.5 156.2 54.8
3 264.1 86.1 67.4
4 253.3 125.1 50.6
5 352.4 198.7 43.5
6 215.4 96.1 55.4
7 341.2 173.4 49.2
8 313.1 207.9 33.6
9 287.2 112.6 60.8
10 366.4 171.8 53.1
11 268.7 149.9 62.8
12 237.5 124.5 41.2
13 378.2 252.6 33.2
14 193.4 111.2 42.5
15 273.3 167.3 38.8
16 172.1 94.3 45.2
17 246.5 119.8 51.4
18 294.2 107.1 63.6
19 186.3 96.9 48.0
20 260.1 118.3 54.5
21 358.4 233.0 35.0
22 268.8 138.2 48.6
23 135.1 94.8 66.1
24 242.5 137.3 43.4
25 378.3 186.5 50.7
26 279.6 136.2 51.3
27 346.9 197.4 43.1
28 357.5 175.5 50.9
29 251.8 148.6 41.0
30 403.2 162.5 59.7
31 243.0 109.6 54.9
32 238.9 123.5 48.3
33 341.9 146.0 57.3
34 251.7 142.2 43.5
35 338.7 169.0 49.9
36 361.4 221.5 38.7
37 252.3 122.4 51.5
38 239.9 121.9 49.2
39 348.3 181.8 47.8
40 339.1 167.5 50.6
cont. Æ
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Table 4. continued
41 249.8 151.9 39.2
42 189.2 80.2 57.6
43 238.6 137.0 42.6
44 277.1 143.3 48.3
45 358.6 180.7 49.6
46 249.1 126.8 49.3
47 341.2 141.9 58.4
48 271.9 141.1 48.1
49 202.3 86.4 57.3
50 368.1 141.3 61.6
51 338.9 160.0 48.2
52 287.3 125.6 56.3
53 358.4 185.7 48.2
54 283.7 159.7 43.7
55 301.6 134.8 55.3
56 259.5 137.8 46.9
57 347.3 161.8 53.4
58 248.9 126.4 49.2
59 297.3 141.5 52.4
60 232.1 122.6 47.2
Mean 286.50 142.86 49.94
involvement of matrix proteases, including metallo-
proteinases, serine and cysteine peptidases, was dem-
onstrated in key functions linked to tumor develop-
ment. It was shown that, apart from turnover of ex-
tracellular matrix, the enzymes are active in recipro-
cal autoactivation within the protein cascades,
associated with tumor development. Recognition of
the transformations promotes development of novel
strategies of anti-neoplastic therapy, linked to inhibi-
tion of selected proteolytic enzymes in specific patho-
physiological processes. Until now, it has been shown
that enzymes of cysteine peptidase family fulfil key
roles in processes of tumor development, such as ap-
optosis, angiogenesis, cell proliferation and invasion.
Until now, the results have been confirmed mainly in
cell lines of human tumors developing in transgenic
mice [19, 20]. Activity of cathepsins B and L was in-
hibited also in vivo, in the blood of patients with la-
ryngeal cancer using autogenous inhibitors isolated
from the urine of the patients [21] or placenta and
amniotic fluid of experimental animals [22], while the
subsequent source of inhibitor isolation involved egg
proteins in order to obtain sufficient amounts of the
inhibitor to perform a series of experiments, aimed
at defining the potential of using the inhibitors to al-
ter activity of enzymes linked to neoplastic processes
in vivo [23]. The latter inhibitor was selected on pur-
pose, since cystatin from hen eggs resembles in its
structure autogenous cystatins present in the human
body [14]. The inhibitor was also found to resemble
in structure human cystatin SN, the activity of which
is strictly correlated with levels of typical tumor mark-
ers, such as CE or CE 19-9 in patients with colorectal
carcinoma [13]. Another autogenic inhibitor, cysta-
tin C, was examined as a potential factor able to con-
trol enzymes specific for neoplastic processes. Despite
satisfactory results on neoplastic process control by
autogenous inhibitors present in the patient’s body,
inhibitors of cysteine peptidases could not have been
used in treatment due to a number of problems asso-
ciated with production of e.g. cystatin C [24]. In oth-
er studies, cystatin of hen eggs has been used follow-
ing its pre-labeling with radioactive iodine 125I.
This study aimed at using the inhibitor mainly to
selectively label individual human cancer cells. The
preparation was also used in an in vivo experiment
obtaining delineation of tissues and organs in which
human tumors developed following their grafting to
transgenic mice. Employing scintigraphy, the 125I-la-
beled cystatins bound in almost 98% only to cancer-
ous cells, yielding in tumor-grafted animals clear out-
lines of organs in which the tumor developed [25].
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Inhibitors isolated from egg protein or placenta
were also used to determine sites of their binding in
neoplastic tissues. The complexes were found to ap-
pear in sites with presence of cathepsin B or at the
limit of neoplastic invasion. In preparations of neo-
plastic tissues obtained from cancerous patients, the
sites in which enzyme-inhibitor complexes appeared
were determined using a modified immunohisto-
pathological technique [26, 27]. Inhibitors of cysteine
peptidases may be applied in extracorporeal therapy
or in preparation of new generation targeted drugs,
taking advantage of affinity linked to cathepsin B,
which is present in tumor cell membranes, affinity to
nanocapsule-bound egg cystatin. The toxic cytostatic
drug, isolated from a patient’s body by the nanocap-
sule, will not be released until the nanocapsule reaches
the site in the body with overexpression of cysteine
peptidases or tissues manifesting tumorous traits.
Moreover, a technique has been devised to remove
from the blood of cancerous patients active cysteine
peptidases or cancerous cells, which in their cell mem-
branes carry the enzymes [28–30].
Summary
For years, attempts have continued to find inhibitors
not toxic for the body which would be able to inhibit
enzymatic processes associated with tumor develop-
ment, including development of colorectal cancer.
Such inhibitors include egg protein cystatins, geneti-
cally similar to their analogs present in the human
body. They have been found to inhibit activity of
cathepsins B and L, regarded as representing enzymes
linked to key cancerous processes. Significant progress
in the development of research involves the results of
studies conducted in the Medical University in Wro-
claw, in which a new, efficient and economic method
has been designed to isolate the inhibitors on a broad
scale. This allows for studies aimed at their use in vit-
ro to inhibit neoplastic processes, and it opens up the
possibility of a new trend in anti-neoplastic therapy,
i.e. inhibitor therapy.
Conclusions
1. Activity of cathepsins B and L increases in the
neoplastic tissues of the large intestine.
2. Cystatins from egg protein control the activity of
cathepsins B and L in vitro in colorectal cancer
tissue.
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